
    
      This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1),
      parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age
      children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up
      to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The
      total duration of the study is up to 10 weeks.
    
  